| OAB0302 | HIV among mpox cases: clinical characteristics and outcomes in the WHO global surveillance 2022 | Oral abstract session with live Q&A | Co-infections (including opportunistic infections) |
| OAB0205 | Lenacapavir oral bridging maintains efficacy with a similar safety profile when SC LEN cannot be administered | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OAB0204 | High rates of long-term HIV RNA re-suppression after virological failure on dolutegravir in the ADVANCE trial | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OAB0203 | Weight and body composition after switch to doravirine/islatravir (DOR/ISL) 100/0.75mg once daily: week 48 results from 2 randomized active-controlled phase 3 trials, MK8591A-017 (P017) and MK8591A-018 (P018) | Oral abstract session with live Q&A | Clinical complications of HIV and antiretroviral therapy |
| OAB0202 | Prior M184V/I and multiple prior virological failures have no impact on the efficacy of switching HIV+ adults to DTG/3TC through 96Wks in SOLAR-3D | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OAB0105 | Virological dynamics among children living with HIV transitioned to a dolutegravir-based regimen in Nigeria | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| OAB0104 | Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed pregnant women with HIV | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |
| OAB0103 | Is the recommended valganciclovir dosing for treatment of cytomegalovirus in infants adequate for treatment of cytomegalovirus pneumonia in HIV-positive infants in sub-Saharan Africa? A pharmacokinetic sub-study in the EMPIRICAL trial | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| OAB0102 | Persistent accelerated epigenetic aging is associated with altered neuroimaging and immune biomarkers in a longitudinal cohort of vertically-acquired HIV-positive adolescents | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| OAA0405 | Protective efficacy of intranasal vaccination with a Sendai virus vector expressing a spike antigen against SARS-CoV-2 infection in mice | Oral abstract session with live Q&A | SARS-CoV-2 virology, pathogenesis, and host immune responses, vaccines and immunotherapies |